Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Subscribe To Our Newsletter & Stay Updated